Browse the evidence

Myostatin acts as a central negative regulator of skeletal muscle mass by inhibiting myoblast proliferation, increasing ubiquitin-proteasomal activity, and downregulating the IGF-Akt pathway.

Myostatin is a key biological brake on muscle growth. While you cannot directly control myostatin levels through simple lifestyle changes, understanding its role explains why muscle loss occurs in disease, aging, and disuse. Interventions that inhibit myostatin (currently experimental in humans) show potential for treating muscle-wasting diseases, but natural resistance training may chronically lower basal myostatin expression to facilitate hypertrophy.

Mitochondrial dysfunction and elevated ROS production drive lipid peroxidation, which contributes to biological aging and age-related diseases.

Focus on maintaining mitochondrial health through lifestyle factors that support energy metabolism and reduce oxidative stress, as these are key drivers of aging and age-related diseases.

Metformin treatment is associated with reduced cancer risk, potentially through AMPK activation and inhibition of mTOR.

Metformin is associated with reduced cancer risk in diabetic patients, possibly via AMPK/mTOR pathways. This is a potential therapeutic avenue, not a lifestyle recommendation.

Women with prior gestational diabetes mellitus (pGDM) exhibit significantly lower plasma adiponectin concentrations compared to women with normal glucose tolerance (NGT), independent of body fat mass and insulin sensitivity.

If you have a history of gestational diabetes, your body likely produces less of a protective hormone called adiponectin than women who did not have GDM, even if your weight is normal. This is a known risk factor for developing type 2 diabetes and cardiovascular issues. You should prioritize regular monitoring of your blood sugar and insulin sensitivity, as your body may be more prone to insulin resistance than the general population.

In insulin-resistant women with prior GDM, plasma adiponectin levels decrease further over a 1-year follow-up period, even in the absence of changes in body weight, body fat composition, or glucose tolerance.

If you have a history of GDM and are insulin-resistant, your protective adiponectin levels may drop over time even if you maintain your weight. This suggests that metabolic health can decline independently of body composition. Regular monitoring of insulin sensitivity is crucial to catch this decline early.

Lower plasma adiponectin in women with prior GDM is associated with subclinical inflammation, indicated by higher levels of C-reactive protein (CRP) and plasminogen activator inhibitor-1 (PAI-1).

Low adiponectin in women with a history of GDM is linked to higher levels of inflammation markers like CRP and PAI-1. This suggests that the hormonal imbalance contributes to a state of subclinical inflammation, which is a risk factor for cardiovascular disease.

Obesity is associated with significantly lower gut microbiota diversity and distinct taxonomic shifts, including decreased Akkermansia and increased Acidaminococcus, independent of dietary intake.

Your gut bacteria differ between normal weight and obese states, with obese individuals showing less diversity and specific bacterial shifts (like lower Akkermansia). This suggests that microbiota composition is a biological factor in obesity, independent of just what you eat. While this doesn't prescribe a specific treatment, it highlights that gut health is a key area of interest in obesity research.

Roux-en-Y gastric bypass (RYGB) induces type 2 diabetes remission primarily by restoring beta-cell glucose sensitivity, whereas improvements in insulin sensitivity are proportional to weight loss and do not independently predict remission.

For patients undergoing gastric bypass, weight loss alone does not guarantee diabetes remission. The key biological factor is the recovery of the pancreas's ability to sense and respond to glucose (beta-cell sensitivity). Patients with severe initial beta-cell dysfunction may not achieve remission even with significant weight loss. Monitoring metabolic markers beyond weight is crucial.

During short-term caloric restriction (800 kcal/day), switching from a standard mixed diet to a ketogenic diet increases the rate of total weight loss solely through increased water excretion, with no significant difference in the rate of fat loss between the two diets.

If you are trying to lose fat, the speed at which you lose fat is determined by your calorie deficit, not whether you eat carbs or not. A ketogenic diet might make the scale drop faster initially due to water loss, but you are not burning fat faster than if you ate a standard low-calorie diet. Focus on maintaining your calorie deficit consistently.

In vitro digestion using the INFOGEST protocol demonstrates that intact proteins from diverse sources (whey, collagen, zein, legumes, cereals) are fully hydrolyzed during the intestinal phase, although digestion-resistant peptides persist in all substrates.

When you eat protein from any source (meat, dairy, beans, grains), your digestive system breaks down the large protein structures into smaller peptides during the intestinal phase. While some resistant peptides remain, the large intact proteins are gone. This suggests that digestive capability is not the primary limiting factor for plant vs. animal protein absorption in a healthy gut.

Long-term high-protein diets (≥25% energy) do not provide superior weight loss, fat loss, or cardiovascular risk reduction compared to low-protein diets when both are low-fat.

If you are trying to lose weight or improve heart health over the long term, simply increasing your protein intake (to ≥25% of calories) will not give you an advantage over a standard low-protein diet, provided both diets are low in fat and you maintain a caloric deficit. Focus on total energy intake and fat quality rather than maximizing protein.

For individuals consuming a balanced diet, calcium and vitamin D supplementation provides little to no beneficial or detrimental effect on fracture prevention.

If you eat a balanced diet and are not on osteoporosis medication, you likely do not need calcium or vitamin D supplements for fracture prevention. Focus on getting these nutrients from food. If you are on medication or have a deficiency, your doctor may recommend specific doses.

Home sleep monitoring devices can distinguish between obstructive and central sleep apnea phenotypes using cardiopulmonary coupling metrics, even without being approved for diagnosis.

If you have known sleep apnea, some advanced home monitors (like M1/SleepImage) may help distinguish between obstructive and central types using heart rate variability patterns, but this is not a diagnostic tool. Consult a physician for diagnosis and treatment.

Advancing age is not associated with increased self-reported sleep disturbance or daytime tiredness; instead, these complaints generally decline across the life span, with the lowest prevalence in individuals older than 80 years.

If you are over 60 and struggling with sleep or fatigue, do not assume it is 'just aging.' This study of over 150,000 Americans shows that the oldest adults (80+) actually report the lowest levels of sleep disturbance and tiredness. Your symptoms are likely driven by modifiable factors like general health status or mood, not your age itself. Addressing underlying health issues or mood disorders may resolve sleep complaints more effectively than accepting them as a natural part of aging.

In postmenopausal women, higher levels of bioavailable testosterone are associated with an increased risk of incident type 2 diabetes, but this association is entirely mediated by adiposity (BMI) and insulin resistance.

For postmenopausal women, high testosterone levels are a warning sign of metabolic risk, but they are not the root cause. The risk comes from excess body fat and insulin resistance. Managing weight and insulin sensitivity is the primary way to mitigate this risk, rather than targeting testosterone levels directly.

In postmenopausal women, higher levels of estradiol (E2) and lower levels of sex hormone-binding globulin (SHBG) are associated with an increased risk of incident type 2 diabetes, and these associations persist even after adjusting for adiposity and insulin resistance.

For postmenopausal women, both high estradiol and low SHBG are independent risk factors for type 2 diabetes, even if you are not overweight. These hormones may directly affect glucose metabolism. Monitoring these levels alongside standard metabolic markers can provide a more complete picture of diabetes risk.

Hypertrophic white adipocytes in obesity trigger chronic low-grade inflammation via macrophage infiltration, contributing to insulin resistance.

In obesity, fat cells can become so large that they trigger an inflammatory response, attracting immune cells that worsen insulin resistance. Reducing fat cell size through weight loss can help resolve this inflammation and improve metabolic health.

Insulin-resistant first-degree relatives of NIDDM patients exhibit a significantly higher percentage of type IIb muscle fibers compared to matched controls, and this morphological trait is a primary determinant of reduced insulin-stimulated glucose disposal.

If you have a family history of Type 2 diabetes, you may naturally have more fast-twitch (Type IIb) muscle fibers, which are less efficient at handling glucose under insulin stimulation. This is not a life sentence; the study links this trait to lower aerobic fitness. Prioritizing aerobic exercise (improving Vo2max) is a key strategy to counteract this specific morphological risk factor for insulin resistance.

Deficiency in the histone demethylase JHDM2a causes adult-onset obesity, metabolic syndrome, and insulin resistance in mice through reduced energy expenditure and impaired fat oxidation.

This research highlights that obesity is not just about calories in vs. calories out, but also involves complex epigenetic regulation of how your body burns fat. In mice, a specific enzyme (JHDM2a) controls genes that determine energy expenditure. When this enzyme is missing, the body burns less fat and stores more, leading to obesity regardless of food intake. This suggests that metabolic health is deeply tied to gene expression regulation, not just behavior.

Endoscopic gastric plication (pose procedure) produces statistically significant but clinically modest weight loss (mean 4.95% TBWL) compared to sham, failing to meet pre-specified superiority margins, while demonstrating a manageable safety profile with transient adverse events.

This procedure involves placing sutures inside the stomach to reduce its capacity. It is a single, minimally invasive procedure followed by basic lifestyle counseling. While the average weight loss is modest (around 5% of body weight), it is statistically better than a sham procedure and can significantly improve conditions like diabetes and high blood pressure. It is an option for those with Class I or II obesity who want more than lifestyle changes but are not candidates for or willing to undergo traditional surgery. Most side effects like pain and nausea resolve within a week.

Concurrent training for strength and endurance results in less adaptation (specifically reduced strength gains) compared to training for either modality alone, due to molecular interference between the PKB and AMPK signaling pathways.

If your primary goal is building muscle or strength, avoid long-duration endurance cardio immediately before or after your weights. If your primary goal is endurance, limit heavy resistance training. The molecular signals for muscle growth (PKB) and mitochondrial efficiency (AMPK) fight each other, so doing both optimally at the same time leads to inferior results for both.

Extending nightly fasting duration is associated with improved glucoregulation (lower HbA1c) and longer sleep duration, which are proposed mechanisms for the reduced breast cancer recurrence risk.

A longer nightly fast helps your body regulate blood sugar better and may help you sleep longer. These improvements in metabolic health and sleep are likely why extending your fast might help prevent breast cancer from coming back.

High intake of simple carbohydrates (sucrose, fructose) and high-fat diets disrupt PPAR-alpha and PPAR-gamma balance, leading to reduced beta-oxidation and increased lipogenesis, which drives NAFLD progression.

Both high-fat and high-sugar diets contribute to fatty liver. Reducing intake of added sugars (especially fructose and sucrose) and saturated fats helps restore the balance of PPAR-alpha and PPAR-gamma, reducing liver fat accumulation.

Elevated levels of C18:0 sphingolipids (specifically ceramide) in skeletal muscle are associated with insulin resistance in humans, independent of body weight or obesity status.

If you are overweight or obese, your risk for insulin resistance is not determined by your weight alone. Some individuals with excess body fat maintain high insulin sensitivity, while others do not. This difference is linked to specific lipid levels (C18:0 sphingolipids) in your muscles. While you cannot easily measure this at home, the takeaway is that 'metabolically healthy obesity' exists, and metabolic health should be assessed independently of BMI.